Levalbuterol

For adults and adolescents aged 12 years and older, the standard dosing for levalbuterol depends heavily on the delivery method and the severity of the respiratory distress.

• Inhalation Solution (Nebulizer): The typical starting dose is 0.63 mg administered three times a day (every 8 hours) via nebulization. If the patient does not respond adequately, the dose may be increased to 1.25 mg three times a day. Patients with more severe bronchospasm or those who are being transitioned from higher doses of racemic albuterol may require the 1.25 mg dose immediately.
• Metered-Dose Inhaler (MDI): The standard recommendation is 2 inhalations (90 mcg) every 4 to 6 hours. In some clinical scenarios, a single inhalation (45 mcg) every 4 hours may be sufficient for mild symptoms. During an acute exacerbation, a healthcare provider may direct the patient to use the inhaler more frequently, but this should only be done under medical supervision.

Levalbuterol is approved for use in children, but the dosage and delivery method are age-dependent.

• Children 6 to 11 years old: The recommended dose via nebulizer is 0.31 mg administered three times a day. The dose should not exceed 0.63 mg three times a day. For the MDI (Xopenex HFA), the dose is typically 2 inhalations every 4 to 6 hours.
• Children 0 to 5 years old: The safety and efficacy of the MDI have not been established in this age group. However, the nebulizer solution is often used off-label or under specific pediatric protocols. For children in this range, the 0.31 mg dose is the most common starting point, though clinical trials for children under 6 have shown varying results regarding the optimal dose.

Renal Impairment

Levalbuterol is primarily excreted by the kidneys. While specific dosage adjustment tables are not provided by the manufacturer, caution should be exercised when administering high doses to patients with significantly impaired renal function. Monitoring for systemic toxicity (such as increased heart rate) is recommended in these individuals.

Hepatic Impairment

Since levalbuterol is not significantly metabolized by the liver's cytochrome P450 system, hepatic impairment does not typically require a dose adjustment. However, as with any medication, the patient's overall clinical status should be considered.

Elderly Patients

Clinical studies of levalbuterol did not include sufficient numbers of subjects aged 65 and older to determine whether they respond differently than younger subjects. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

Proper administration is the most important factor in ensuring the medication reaches the lungs where it is needed.

1. 1Nebulizer Use: Open the foil pouch and remove one unit-dose vial. Squeeze the entire contents into the nebulizer reservoir. Connect the nebulizer to the compressor. Breathe calmly and deeply through the mouthpiece until the mist stops (usually 5 to 15 minutes). Always use a fresh vial for each treatment.
2. 2MDI (Inhaler) Use: Shake the inhaler well before each use. If using for the first time or if the inhaler has not been used for more than 3 days, 'prime' it by spraying 4 test puffs into the air away from your face. Exhale completely, place the mouthpiece in your mouth, and begin to inhale slowly while pressing down on the canister. Hold your breath for 10 seconds to allow the drug to settle in the lungs. Wait at least 1 minute between puffs.
3. 3Storage: Store levalbuterol at room temperature (68°F to 77°F). Keep the vials in their protective foil pouch to protect them from light. Once a pouch is opened, the vials should be used within 2 weeks. If the solution is not clear and colorless, discard it.

If you miss a dose of levalbuterol, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and return to your regular schedule. Do not double the dose to catch up. Since levalbuterol is often used 'as needed' for symptoms, a missed dose may not be an issue unless you are on a fixed schedule for maintenance.

An overdose of levalbuterol can be serious due to its effects on the heart and electrolyte balance. Symptoms of overdose include:

• Severe chest pain (angina)
• Rapid or irregular heartbeat (tachycardia/arrhythmias)
• Significant tremors or shaking
• Severe headache
• Nervousness or anxiety
• Seizures
• Low potassium levels (hypokalemia), which can cause muscle weakness or heart rhythm issues.

In the event of a suspected overdose, contact your local poison control center or seek emergency medical attention immediately. Treatment usually involves supportive care and monitoring of cardiac function and serum potassium levels.

> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance. Excessive use of SABA inhalers can be a sign that your asthma is not well-controlled and may require a change in your 'controller' medication (like inhaled steroids).

Common side effects of levalbuterol are typically related to its 'sympathomimetic' nature—meaning it stimulates the nervous system similarly to adrenaline. These effects are often dose-dependent and may diminish as your body adjusts to the medication.

• Nervousness and Anxiety: Many patients report a feeling of 'jitteriness' or inner restlessness. This occurs because the drug can cause minor stimulation of the central nervous system.
• Tremor: Involuntary shaking, particularly in the hands, is a hallmark side effect of beta-agonists. This is caused by the stimulation of beta2-receptors in the skeletal muscles.
• Headache: This is one of the most frequently reported side effects in clinical trials. It is usually mild to moderate and tends to resolve shortly after the treatment ends.
• Tachycardia (Rapid Heart Rate): You may feel like your heart is racing or 'fluttering' in your chest. While levalbuterol is designed to be selective for the lungs, it can still affect the heart's beta-receptors.
• Dizziness: Some patients feel lightheaded shortly after inhalation, which may be related to changes in blood pressure or breathing patterns during the treatment.

• Cough and Throat Irritation: The act of inhaling a mist or powder can irritate the upper airways, leading to a dry cough or a sore throat (pharyngitis).
• Dyspepsia (Upset Stomach): Some patients experience nausea or minor stomach discomfort.
• Insomnia: If taken late in the evening, the stimulating effects of levalbuterol may make it difficult to fall asleep.
• Muscle Cramps: Changes in electrolyte balance (specifically potassium) can occasionally lead to localized muscle cramping.
• Palpitations: A sensation that the heart is skipping a beat or pounding forcefully.

• Hypokalemia: A significant drop in blood potassium levels. While rare at standard doses, it can occur with frequent or high-dose usage.
• Hyperglycemia: A temporary increase in blood sugar levels, which is generally only a concern for patients with poorly controlled diabetes.
• Arrhythmias: Abnormal heart rhythms, such as atrial fibrillation, have been reported in rare cases, particularly in patients with pre-existing heart conditions.
• Hypersensitivity Reactions: This includes skin rash, hives (urticaria), and swelling of the face or throat (angioedema).

> Warning: Stop taking Levalbuterol and call your doctor immediately if you experience any of these serious symptoms.

• Paradoxical Bronchospasm: Occasionally, levalbuterol can cause the airways to tighten more immediately after use. If your breathing gets worse right after taking a puff, this is a medical emergency. This reaction is often life-threatening.
• Chest Pain (Angina): If you experience pressure, squeezing, or pain in your chest, it may indicate that the drug is putting too much strain on your heart.
• Severe Allergic Reaction (Anaphylaxis): Symptoms include difficulty breathing, swelling of the tongue or throat, and a rapid drop in blood pressure.
• Signs of Low Potassium: Severe muscle weakness, limp feeling, leg cramps, or a 'fluttering' in the chest.
• Extreme Hypertension: A sudden, severe increase in blood pressure characterized by a 'pounding' headache and blurred vision.

Levalbuterol is intended for acute relief and is not typically associated with permanent long-term side effects when used correctly. However, chronic over-reliance on levalbuterol (using it daily or several times a day for long periods) can lead to:

• Beta-Receptor Downregulation: Over time, the receptors in your lungs may become less sensitive to the drug, meaning it may not work as well as it once did. This is often a sign that your underlying inflammation is not being treated.
• Increased Airway Hyper-responsiveness: Some studies suggest that excessive use of SABAs without concomitant steroid use can make the airways more sensitive to triggers like allergens or cold air.

No FDA black box warnings for Levalbuterol. Unlike Long-Acting Beta-Agonists (LABAs) which once carried black box warnings regarding asthma-related death when used without inhaled corticosteroids, short-acting agonists like levalbuterol do not carry this specific warning. However, the lack of a black box warning does not mean the drug is without risk; the risk of paradoxical bronchospasm is a major safety concern listed in the 'Warnings and Precautions' section of the FDA label.

Report any unusual symptoms to your healthcare provider. Keeping a 'symptom diary' can help your doctor determine if your side effects are dose-related or if a different medication is required.

Levalbuterol is a powerful bronchodilator that must be used with caution. The most critical safety point is that levalbuterol should not be used as the only treatment for patients with persistent asthma. If you find yourself needing to use your levalbuterol inhaler more than two days a week (excluding use before exercise), your asthma may not be well-controlled, and you must consult your healthcare provider about adding a 'controller' medication, such as an inhaled corticosteroid. Over-reliance on 'reliever' medications like levalbuterol is associated with an increased risk of severe asthma attacks and death.

No FDA black box warnings for Levalbuterol.

• Paradoxical Bronchospasm: Like other inhaled medicines, levalbuterol can produce paradoxical bronchospasm, which may be life-threatening. If this occurs, levalbuterol should be discontinued immediately and alternative therapy instituted. It is recognized that paradoxical bronchospasm occurs most frequently with the first use of a new canister or vial.
• Cardiovascular Effects: Levalbuterol, like all sympathomimetic amines, can produce clinically significant cardiovascular effects in some patients. This includes increases in pulse rate and blood pressure. It should be used with extreme caution in patients with underlying cardiovascular disorders, including coronary insufficiency, cardiac arrhythmias, and hypertension.
• Deterioration of Asthma: Asthma may deteriorate acutely over a period of hours or chronically over several days or longer. If the patient needs more doses of levalbuterol than usual, this may be a marker of destabilization of asthma and requires immediate re-evaluation of the treatment regimen.
• Hypokalemia: Beta-agonist medications may produce significant hypokalemia (low blood potassium) in some patients, possibly through intracellular shunting, which has the potential to produce adverse cardiovascular effects. The decrease is usually transient, not requiring supplementation.
• Pre-existing Conditions: Use with caution in patients with convulsive disorders (seizures), hyperthyroidism (overactive thyroid), or diabetes mellitus. Patients with hyperthyroidism may experience exacerbated symptoms, and those with diabetes may experience increased blood glucose levels.

Patients using levalbuterol for chronic management should undergo regular monitoring to ensure the drug remains safe and effective:

• Pulmonary Function Tests: Periodic spirometry (a test that measures how much air you can inhale and exhale) is recommended to assess the status of the underlying lung disease.
• Potassium Levels: In patients taking high doses or those also taking diuretics, periodic monitoring of serum potassium may be necessary.
• Blood Glucose: Diabetic patients should monitor their blood sugar more frequently when starting levalbuterol or increasing the dose.
• Heart Rate and Blood Pressure: Routine checks during office visits to ensure the drug is not causing significant cardiovascular strain.

Levalbuterol generally does not interfere with the ability to drive or operate machinery. However, because some individuals experience dizziness, tremors, or nervousness, you should observe how the medication affects you before engaging in activities that require focus and coordination.

There is no direct chemical interaction between alcohol and levalbuterol. However, alcohol can sometimes trigger asthma symptoms in certain individuals (especially those sensitive to sulfites in wine). Furthermore, excessive alcohol consumption can impair your ability to recognize worsening asthma symptoms or use your inhaler correctly in an emergency.

Levalbuterol does not typically require a 'tapering' period because it is a short-acting medication used for symptom relief. However, you should never stop taking your other asthma medications (like steroid inhalers) just because you feel better after using levalbuterol. Stopping controller medications can lead to a severe rebound in inflammation and airway constriction.

> Important: Discuss all your medical conditions with your healthcare provider before starting Levalbuterol. Ensure your provider knows if you have a history of heart disease, high blood pressure, or thyroid problems.

While few drugs are strictly 'contraindicated' with levalbuterol, certain combinations are avoided due to the high risk of severe adverse events:

• Non-Selective Beta-Blockers (e.g., Propranolol): These drugs are the direct 'antagonists' of levalbuterol. Beta-blockers not only block the bronchodilatory effect of levalbuterol but may also produce severe bronchospasm in patients with asthma. If a beta-blocker is required (e.g., after a heart attack), a cardioselective beta-blocker (like Atenolol or Metoprolol) should be considered, but used with extreme caution.

• Monoamine Oxidase Inhibitors (MAOIs) and Tricyclic Antidepressants (TCAs): Drugs like phenelzine, selegiline, amitriptyline, or nortriptyline can potentiate the action of levalbuterol on the vascular system. This can lead to severe hypertension (high blood pressure) or arrhythmias. Levalbuterol should be administered with extreme caution to patients being treated with these agents, or within two weeks of discontinuation of such agents.
• Diuretics (Loop or Thiazide): Non-potassium-sparing diuretics (like furosemide or hydrochlorothiazide) can cause potassium loss. Since levalbuterol can also lower potassium, the combination may result in ECG changes or clinically significant hypokalemia.

• Digoxin: Studies have shown that levalbuterol (and other beta-agonists) can decrease serum digoxin levels by up to 16% to 22%. While the clinical significance for a single dose is low, chronic use may require monitoring of digoxin levels to ensure they remain within the therapeutic range.
• Other Sympathomimetic Agents: Using levalbuterol with other short-acting sympathomimetic bronchodilators (like racemic albuterol) is not recommended, as it increases the risk of cardiovascular toxicity. If additional adrenergic drugs are to be administered by any route, they should be used with caution to avoid deleterious cardiovascular effects.

• Caffeine: Caffeine is a methylxanthine that has mild bronchodilatory properties but also acts as a stimulant. Consuming high amounts of caffeine (coffee, energy drinks) while using levalbuterol can increase the likelihood of experiencing tremors, nervousness, and a rapid heart rate.
• Sulfites: While not an interaction with the drug itself, some nebulizer solutions may contain sulfites (though many levalbuterol formulations are sulfite-free). Patients with known sulfite sensitivity should verify the inactive ingredients with their pharmacist.

• St. John's Wort: While primarily known for interacting with CYP450 enzymes (which levalbuterol does not use), St. John's Wort can have mild stimulant effects that may compound the nervousness associated with levalbuterol.
• Ephedra (Ma Huang): This herbal supplement contains ephedrine, a potent stimulant. Combining ephedra with levalbuterol is dangerous and can lead to severe heart palpitations, high blood pressure, and even stroke or heart attack.
• Bitter Orange: Contains synephrine, which may increase heart rate and blood pressure when combined with beta-agonists.

Levalbuterol may interfere with the results of certain laboratory tests:

• Serum Potassium: May show falsely low levels (hypokalemia).
• Blood Glucose: May show transiently elevated levels (hyperglycemia).
• Exercise Stress Tests: Since levalbuterol increases heart rate, it may interfere with the accuracy of cardiac stress testing. Inform your technician if you have used your inhaler within 12 hours of the test.

For each major interaction, the mechanism usually involves either 'pharmacodynamic antagonism' (drugs working against each other) or 'pharmacodynamic synergism' (drugs adding together to cause too much of an effect).

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking. This includes over-the-counter cold medicines, which often contain stimulants that can interact with levalbuterol.

There are very few absolute contraindications for levalbuterol because it is often a life-saving medication during acute respiratory distress. However, it must NEVER be used in the following case:

• Hypersensitivity to Levalbuterol or Albuterol: If you have had a documented severe allergic reaction (anaphylaxis, angioedema, or severe rash) to levalbuterol hydrochloride or racemic albuterol, you must not use this medication. The chemical structures are nearly identical, and cross-reactivity is guaranteed. Using the drug in these cases could lead to a fatal allergic response.

Relative contraindications are conditions where the drug should only be used if the benefit clearly outweighs the risk, and only under close medical supervision:

• Severe Cardiac Disease: This includes patients with unstable angina, recent myocardial infarction (heart attack), or severe underlying arrhythmias. The stimulating effect of levalbuterol can increase myocardial oxygen demand, potentially worsening these conditions.
• QT Prolongation: Patients with a history of long QT syndrome (an electrical heart rhythm disorder) may be at higher risk for further prolongation and dangerous 'torsades de pointes' rhythms when using high doses of beta-agonists.
• Severe Hypertension: In patients with uncontrolled high blood pressure, the vasoconstrictive potential (at high doses) and increased heart rate can lead to hypertensive crises.
• Thyrotoxicosis: Patients with an overactive thyroid are already in a 'hyper-metabolic' state. Levalbuterol can worsen the symptoms of tachycardia and tremors associated with this condition.

As mentioned, there is a 100% cross-sensitivity between levalbuterol and racemic albuterol. If you are allergic to ProAir, Ventolin, or AccuNeb (brands of albuterol), you will also be allergic to Xopenex (levalbuterol). There is also a potential for cross-sensitivity with other beta-agonists like salmeterol or formoterol, though this is less common. Patients with a history of 'paradoxical bronchospasm' with any inhaled beta-agonist should be monitored with extreme caution when starting levalbuterol.

> Important: Your healthcare provider will evaluate your complete medical history before prescribing Levalbuterol. Always disclose any previous 'bad reactions' to inhalers, even if they seemed minor at the time.

Levalbuterol was previously classified as FDA Pregnancy Category C. This means that animal reproduction studies have shown an adverse effect on the fetus, but there are no adequate and well-controlled studies in humans.

• Teratogenicity: In animal studies (mice), large doses of racemic albuterol were associated with the development of cleft palate. However, it is important to note that poorly controlled asthma poses a much greater risk to both the mother and the fetus (including preeclampsia, low birth weight, and preterm delivery).
• Labor and Delivery: Because of the potential for beta-agonist interference with uterine contractility, use of levalbuterol for relief of bronchospasm during labor should be restricted to those patients in whom the benefits clearly outweigh the risk. Beta-agonists are sometimes used 'off-label' to stop premature labor (tocolysis), but levalbuterol is not approved for this purpose.

It is not known whether levalbuterol is excreted in human milk. Because of the potential for tumorigenicity shown for albuterol in animal studies and the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. Most clinical experts suggest that the amount of drug reaching the infant via breast milk after maternal inhalation is likely to be clinically insignificant, but caution is still advised.

• Nebulizer Solution: Approved for use in pediatric patients as young as newborns in some clinical settings, though the official FDA labeling focuses on children 6 years and older for certain concentrations. The 0.31 mg dose is specifically designed for younger children to minimize systemic exposure.
• Metered-Dose Inhaler (HFA): Approved for children 4 years of age and older.
• Growth Effects: There is no evidence that short-acting beta-agonists like levalbuterol affect growth in children, unlike inhaled corticosteroids which require monitoring of growth velocity.

Elderly patients (65 years and older) are more likely to have underlying cardiac conditions or be taking medications like diuretics or beta-blockers that interact with levalbuterol.

• Cardiac Sensitivity: The aging heart may be more sensitive to the tachycardic effects of levalbuterol.
• Renal Function: Since the drug is renally excreted, and kidney function naturally declines with age, there is a higher risk of systemic accumulation in the elderly. Healthcare providers usually start with the lowest effective dose (0.63 mg or 0.31 mg via nebulizer).

Levalbuterol is primarily eliminated by the kidneys. In patients with a GFR (Glomerular Filtration Rate) of less than 30 mL/min, the clearance of the drug may be reduced. While specific dose-adjustment guidelines are not established, these patients should be monitored for signs of systemic beta-agonist toxicity, such as persistent tremors or palpitations. It is not significantly removed by hemodialysis.

The liver does not play a major role in the primary clearance of levalbuterol. Therefore, no specific dose adjustments are typically required for patients with mild to moderate hepatic impairment (Child-Pugh Class A or B). In severe hepatic impairment, the general clinical status of the patient should guide therapy.

> Important: Special populations require individualized medical assessment. Always inform your specialist if you are pregnant or planning to become pregnant while using respiratory medications.

Levalbuterol is the (R)-enantiomer of the racemic bronchodilator albuterol. It is a highly selective beta2-adrenergic receptor agonist. Its primary action is to stimulate adenyl cyclase, the enzyme which catalyzes the formation of cyclic-3',5'-adenosine monophosphate (cAMP) from adenosine triphosphate (ATP). The increased cAMP levels are associated with the relaxation of bronchial smooth muscle and the inhibition of the release of mediators of immediate hypersensitivity from cells, especially mast cells.

By increasing cAMP, levalbuterol also activates protein kinase A, which inhibits the phosphorylation of myosin and lowers intracellular calcium. This is a critical molecular pathway because calcium is the primary 'trigger' for muscle contraction. By 'mopping up' or sequestering this calcium, levalbuterol ensures the airways remain open even in the presence of inflammatory triggers.

• Onset of Action: Rapid. Following inhalation, bronchodilation typically begins within 5 to 15 minutes.
• Peak Effect: The maximum improvement in lung function (measured by FEV1) usually occurs 60 to 90 minutes after administration.
• Duration of Action: The therapeutic effects generally last between 3 to 6 hours, although in some patients, it may persist for up to 8 hours.
• Tolerance: With frequent use, 'tachyphylaxis' (a rapid decrease in response to the drug) can occur, although this is more common with long-acting agonists than with levalbuterol.

| Parameter | Value |

|---|---|

| Bioavailability | ~10-20% (Pulmonary); ~80% (Systemic/Swallowed) |

| Protein Binding | 7% to 10% |

| Half-life | 3.3 to 4.8 hours |

| Tmax (Peak Time) | 0.2 to 1.5 hours |

| Metabolism | Primarily via Sulfotransferase (SULT1A3) in GI/Liver |

| Excretion | Renal 80-100% (as parent drug and sulfate metabolite) |

• Molecular Formula: C13H21NO3 (as levalbuterol base)
• Molecular Weight: 239.31 g/mol
• Solubility: Soluble in water; sparingly soluble in ethanol.
• Structure: Levalbuterol is a phenethylamine derivative. It consists of a benzene ring with hydroxyl groups at the 3 and 4 positions (a catecholamine-like structure) and a tert-butylamino group. The (R)-configuration at the chiral center is what defines its high affinity for the beta2-receptor.

Levalbuterol is classified as a Short-Acting Beta2-Adrenergic Agonist (SABA). It belongs to the broader class of sympathomimetic amines. Related medications include racemic albuterol (Ventolin, ProAir), pirbuterol (Maxair), and terbutaline. It is distinct from Long-Acting Beta-Agonists (LABAs) like salmeterol, which have a much longer duration of action and are not used for acute relief.